Хронический атрофический гастрит: диагностическое и прогностическое значение иммунного ответа на инфекцию Helicobacter pylori
Анализ продукции антител к различным антигенам бактерии Helicobacter pylori у больных с хроническим гастритом, ранним раком желудка. Использование результатов исследования в скрининге пациентов с высоким риском развития атрофии слизистой оболочки желудка.
| Рубрика | Медицина |
| Вид | диссертация |
| Язык | русский |
| Дата добавления | 30.12.2019 |
| Размер файла | 1,9 M |
Отправить свою хорошую работу в базу знаний просто. Используйте форму, расположенную ниже
Студенты, аспиранты, молодые ученые, использующие базу знаний в своей учебе и работе, будут вам очень благодарны.
101. Discrepancy Between Polymerase Chain Reaction Assay and Western Blot Analysis in the Assessment of CagA Status in Dyspeptic Patients / O.A. Paoluzi [et al.] // Helicobacter. - 2001. - Vol.6, N 2. - P. 130-135.
102. Effect of eradication of Helicobacter pylori on incidence of metachronous gastric carcinoma after endoscopic resection of early gastric cancer: an open-label, randomized controlled trial / K. Fukase // Lancet. - 2008. - Vol. 372. - P. 392-397.
103. Effect of Helicobacter pylori eradication on malignant transformation of gastric adenoma / K. Saito [et al.] // Gastrointest Endosc. - 2000. - Vol.52. - P. 27-32.
104. Effectiveness and pharmaceutical cost of sequential treatment for Helicobacter pylori in patients with nonulcer dyspepsia / V. De Francesco [et al.] // Aliment. Pharmacol. Ther. - 2004.- Vol. 19. - P. 993-998.
105. Effectiveness of a 10-day sequential treatment for Helicobacter pylori eradication in clinical practice / J. Delgado [et al.] // Gastroenterology. - 2007. - Vol. 132. - P. 112.
106. Epidemiologic features of upper gastrointestinal tract cancers in Northeastern Iran / F. Islami [et al.] // Br J Cancer. - 2004. - N 90. - Р. 1402-1406.
107. Epidemiological trends of pre-malignant gastric lesions; a long-term nationwide study in the Netherlands / A.C. De Vries [et al.] // Gut. - 2007. - 56. - Р. 1665-70.
108. EUROCARE-3 summary: cancer survival in Europe at the end of the 20th century / M.P. Coleman [et al.] // Ann. Oncol. - 2003. - Vol. 5 (suppl. 14). - P. 128-149.
109. Evaluation of Gastric Atrophy. Comparison between Sidney and OLGA Systems / P. Ramнrez-Mendoza, J. Gonzбlez-Angulo, U. Angeles-Garay, G.A. Segovia-Cueva //Rev Med Inst Mex Seguro Soc. - 2008. - 46 (2). - Р. 135-9.
110. Ferlay J. GLOBOCAN 2002: cancer incidence, mortality and prevalence world-wide / J. Ferlay, F. Bray, P. Pisani. - Lion: IARC Press, 2004.
111. Field cancerization, clonality, and epithelial stem cells: the spread of mutated clones in epithelial sheets / S.B. Garcia [et al.] // J Pathol. - 1999. - N 187. - Р. 61- 81.
112. Functional gastroduodenal disorders / J. Tack [et al.] // Gastroenterology. - 2006. - Vol. 130, N 5. - P. 1466-1479.
113. Fundal atrophic gastritis as a risk factor for gastric cancer / M. Tatsuta [et al.] // Int J Cancer. - 2003. - N 55. - Р. 70-3.
114. Gastric atrophy and intestinal metaplasia before and after Helicobacter pylori eradication: a meta-analysis / J. Wang [et al.] // Digestion. - 2011. - Vol. 83. - P. 253-260.
115. Gastric cancer: basic aspects / C. Resende [et al.] // Helicobacter. - 2011. - Vol. 16 (suppl. 1). - P. 38-44.
116. Gastric cancer: clinical aspects, epidemiology and molecular background / L. Bornschein, T. Rokkas, M. Selgrad, P. Malfertheiner // Helicobacter. - 2011. - Vol. 16 (suppl. 1). - P. 45-52.
117. Gastric cancer risk in patients with premalignant gastric lesions: a nationwide cohort study in the Netherlands / A.C. De Vries [et al.] // Gastroenterology. - 2008. - Vol. 134, N 4. - P. 945-952.
118. Gastric foveolar metaplasia and gastric heterotopia in the duodenum: no evidence of an etiologic role for Helicobacter pylori / R.M. Genta [et al.] // Hum Pathol. - 2010. - N 41(l 1). - P. 1593-1600.
119. Gastritis staging in clinical practice: the OLGA staging system / M. Rugge, A. Meggio, G. Pennelli [et al.] // Gut. - 2007. - N 56. - Р. 631-639.
120. Gene structure of the Helicobucter pylori cytotoxin and evidence of its key role in gastricdisease / J.L. Telford [et al.] // JExpMed. - 2003. - Vol.169. - P. 1653-1659.
121. Gillen D. Effect of H. pylori eradication on precancerous lesions / D. Gillen // Gut. - 2005. - 54. - P.1511.
122. Global cancer statistics, 2002 / D.M. Parkin [et al.] // CA Cancer J. Clin. - 2005. - Vol. 55. - P. 74-108.
123. Gonzales C.A. Helicobacter pylori, nutrition and smoking interactions: their impact in gastric carcinogenesis / C.A. Gonzales, L. Lopez-Carillo // Scand. J. Gastroenterol. - 2010. - Vol. 45. - P. 6-14.
124. Graham D.Y. Eradication of gastric cancer and more efficient gastric cancer surveillance in Japan: two peas in a pod / D.Y. Graham, M. Asaka // J. Gastroenterol. - 2010. - Vol. 45, N 1. - P. 1-8.
125. H. pylori eradication prevents the progression of gastric intestinal metaplasia in reflux esophagitis patients using long-term esomeprazole / H.B. Yang [et al.] // Am J Gastroenterol. - 2009. - N 7. - Р. 1642-9.
126. Helicobacter and Cancer Collaborative Group. Gastric cancer and H. pylori: a combined analysis of 12 case control studies nested within prospective cohorts // Gut. - 2001. - Vol. 49. - P. 347-353.
127. Helicobacter pylori and the development of atrophic gastritis / S. Takahashi [et al.] // Nippon Rinsho. - 2003. - Vol.51(12).- P. 3231-3235.
128. Helicobacter pylori cagA+ strains and dissociation of gastric epithelial cell proliferation from apoptosis / R.M. Jr. Peek [et al.] // J. Natl. Cancer Inst. - 2001. - Vol.79. - P. 763-768.
129. Helicobacter pylori eradication has the potential to prevent gastric cancer: a state-of-the art critique / P. Malfertheiner [et al.] // Am. J. Gastroenterol. - 2005. - Vol. 100. - P. 2100-2115.
130. Helicobacter pylori eradication to prevent gastric cancer in a high-risk region of China: a randomized controlled trial / B.C. Wong [et al.] // JAMA. - 2004. - Vol. 291, N 2. - P. 187-194.
131. Helicobacter pylori infection and gastric histology in first degree relatives of gastric cancer patients: a metaanalysis / T. Rokkas [et al.] // Eur. J. Gastroenterol. Hepatol. - 2011. - Vol. 83. - P. 253-260.
132. Helicobacter pylori infection and the development of gastric cancer / N. Uemura [et al.] // N Engl J Med. - 2001. - N 345. - Р. 784-789.
133. Helicobacter pylori membrane protein 1. A new carcinogenic factor of Helicobacter pylori / M. Suganuma [et al.] // Cancer Res. - 2001. - Vol. 61. - P. 6356-6359.
134. Helicobacter pylori strain-specific differences in genetic content, identified by microarray, influence host inflammatory responses / D.A. Israel [et al.] // J. Clin. Invest. - 2001. - Vol.107. - P. 611-620.
135. High eradication rates of Helicobacter pylori with a new sequential treatment / A. Zullo [et al.] // Aliment. Pharmacol. Ther. - 2003. - Vol. 17. - P. 719-726.
136. High efficacy of 14-day triple therapy-based, bismuth-containing quadruple therapy for initial Helicobacter pylori eradication / Q. Sun [et al.] // Helicobacter. - 2010. - N 15(3). - Р. 233-9.
137. High prevalence of clarithromycin-resistant Helicobacter pylori strains and risk factors associated with resistance in Madrid, Spain / S. Agudo [et al.] //J Clin Microbiol. - 2010. - N 48(10). - Р. 3703-8.
138. Histologic and immunohistochemical analyses of a-fetoprotein--producing cancer of the stomach / T. Kinjo [et al.] // Am J Surg Pathol. - 2012. - N 36 (l). - P. 56-69.
139. Houghton J. Helicobacter pylori and gastric cancer: a new paradigm for inflammation-associated epithelial cancers / J. Houghton, T. C. Wang // Gastroenterology. - 2005. - № 6. - V.128. - P. 1567-1573.
140. Hunt R.H. Risks of untreated H. pylori infection / R. Н. Hunt // AGA Institute Postgraduate Course. - 2006. - P. 333-348.
141. Improved efficacy of 10-day sequential treatment for Helicobacter pylori eradication in children: a randomized trial / R. Francavilla [et al.] // Gastroenterology. - 2005. - Vol. 129. - P. 1414-1419.
142. Increased prevalence of precancerous changes in relatives of gastric cancer patients: critical role of H. pylori / E.M. El Omar [et al.] // Gastroenterology. - 2000. - Vol. 118. - P. 22-30.
143. Increased risk of noncardia gastric cancer associated with proinflammatory cytokine gene polymorphisms / E.M. Omar [et al.] // Gastroenterology. - 2003.- Vol.124.- P. 1193-1201.
144. Indefinite for non-invasive neoplasia lesions in gastric intestinal metaplasia: the immunophenotype / M. Cassaro J [et al.] // Clin Pathol. - 2007. - N 60 (6). - Р. 615-21.
145. Interferon-gamma induced cell death in a cultured human salivary gland cell line / A.J. Wu [et al.] // J Cell Physiol. - 2002. - Vol.163. - P. 297-307.
146. Interferon-gamma induces interleukin-1 converting enzyme expression in pancreatic islets by an interferon regulatory factor-1-dependent mechanism / A.E. Karlsen [et al.] // J Clin Endocrinol Metab. - 2000. - Vol.85. - P. 830-836.
147. Interleukin-1 polymorphisms associated with increased risk of gastric cancer / E.M. El Omar [et al.] // Nature. - 2000. - Vol. 404. - P. 398-402.
148. Investigation of gastric cancer occured in successful H. pylori eradication and persistent H. pylori infected patients / M. Kato [et al.] // Gastroenterology - 2005. - Vol. 128 (suppl. 2). - Abstract M1346.
149. Israel D.A. Review article: pathogenesis of Helicobacter pylori-induced gastric inflammation / D.A. Israel, R.M. Peek // Aliment Pharmacol Ther. - 2001. - Vol.15. - P.1271-1290.
150. Kashiwagi H. Ulcers and gastritis / H. Kashiwagi // J. Tradit Chin Med. - 2004. - Vol.24 (4). - P. 252-255.
151. Kato S. Primary antimicrobial resistance of Helicobacter pylori in children during the past 9 years / S. Kato, S. Fujimura // Pediatr Int. - 2010. - N 52(2). - Р.187-92.
152. Koh T.C. Tumors of the stomach / T.C. Koh, T.C. Wang // Sleisenger and Fordtran's gastrointestinal and liver disease / Ed. Feldman M. [et al.]. - 7th ed. - Philadelphia- London-Toronto-Montreal-Sydney-Tokyo, 2002. - P. 829-855.
153. Kuniyasu H. Helicobacter pylori infection and carcinogenesis of the stomach / H. Kuniyasu, W. Yasui, H. Yokozaki // Langenbecks Arch Surg. - 2000. - Vol. 385, N 2. - P.69-77.
154. Leja M. Gastric cancer: epidemiology, diversity and pathogenesis / M. Leja / GI Oncology and Innovative Aspects in Gastroenterology / Ed. Arnold R. [et al.]. - Paris, 2005. - P. 63-68.
155. Longterm results of gastric cancer screening using the the serum pepsinogen test method among an asymptomatic middle-aged Japanese population / K. Miki [et al.] // Dig. Endosc. - 2009. - Vol. 21, N 2. - P. 78-81.
156. Lu L. Pathologic and physiologic interactions of bacteria with the gastrointestinal epithelium / L. Lu, W.A. Walker // Am J Clin Nutr. - 2001. - Vol.73. - P. 1124S-1130S.
157. MacDonald T.T. Bacterial regulation of intestinal immune responses / T.T. MacDonald, S. Pettersson // Inflamm Bowel Dis. - 2000. - Vol.6. - P. 116-122.
158. Matsumoto M. Posttranslational phosphorylation of mutant p53 protein in tumor development / M. Matsumoto, M. Furihata, Y. Ohtsuki // Med Mol Morphol. - 2006. - N 39(2). - Р. 79-89.
159. Meining A. Features of gastritis predisposing to gastric adenoma and early gastric cancer / A. Meining, B. Riedl, M. Stolte // J Clin Pathol. - 2002. - N 55. - Р.770-5.
160. Metaanalysis of the relationship between CagA seropositivity and gastric cancer / J.Q. Huang [et al.] // Gastroenterology. - 2003. - Vol. 125. - P. 1636-1644.
161. Moayyedi P. Clinical and economic consequences of dyspepsia in the community / P. Moayyedi, J. Mason // Gut 2002. - N 50 (suppl. 4). - Р. 10-13.
162. Morphometric evaluation of gastric antral atrophy: improvement after cure H. pylori infection / B. Ruiz [et al.] // Scand. J. Gastroenterol. - 2002. - Vol.16 (80). - Р. 1449-1456.
163. Narrow band imaging for the detection of gastric intestinal metaplasia and dysplasia during surveillance endoscopy / L.G. Capelle [et al.] // Dig Dis Sci. - 2010. - N 55(12). - P. 3442-3449.
164. Rationale in diagnosis and screening of atrophic gastritis with stomachspecific plasma biomarkers / L. Agreus [et al.] // Scand. J. Gastroenterol. - 2012. - Vol. 47, N 2. - P. 136-147.
165. O'Morain C. Indications for H. pylori treatment / C. O'Morain // Management of H. pylori infection: The Maastricht 4 Consensus. Symposium 19.UEGW. - Stockholm, 2011. - Oral presentation.
166. Prevalence of atrophic gastritis in dyspeptic patients in Piedmont. A survey using the GastroPanel test / L. Lombardo [et al.] // Clin. Chem. Lab. Med. - 2010. - Vol. 48. - P. 1327-1332.
167. Prevalence of primary clarithromycin resistance in Helicobacter pylori strains over a 15 year period in Italy / V. De Francesco [et al.] // J Antimicrob Chemother. - 2007. - 59. - Р. 783-783.
168. Primary clarithromycin resistance to Helicobacter pylori and therapy failure in children: the experience in West Virginia / Y. Elitsur [et al.] // J. Pediatr. Gastroenterol. Nutr. - 2006. - N 42. - Р. 327-331.
169. Progression of chronic atrophic gastritis associated with Helicobacter pylori infection increases risk of gastric cancer / H. Ohata [et al.] // Int. J. Cancer. - 2004. - Vol.109 (1). - P. 138-143.
170. Prospective study of physical activity and risk of primary adenocarcinoma of the esophagus and stomach in the EPIC (European Prospective Investigation into Cancer and Nutrition) cohort / J.M. Huerta [et al.] // Cancer Causes Control. - 2010. - Vol. 21. - P. 657-659.
171. Quantitative detection of Helicobacter pylori gene expression in vivo and relationship to gastric pathology / R.M. Jr. Peek [et al.] // Infect Immunol. - 2000. - Vol.68. - P. 5488-5495.
172. Rationale in diagnosis and screening of atrophic gastritis with stomachspecific plasma biomarkers / L. Agreus [et al.] // Scand. J. Gastroenterol. - 2012. - Vol. 47, N 2. - P. 136-147.
173. Relation of Helicobacter pylori infection and lifestyle to the risk of chronic atrophic gastritis: a cross-sectional study in Japan / K. Shibata [et al.] // J. Epidemiol. - 2002. - Vol. 12, N 2. - P. 105-111.
174. Rodgers C. A meta-analysis of the success rate of Helicobacter pylori therapy in Canada / C. Rodgers, S.V. van Zanten // Can J Gastroenterol. - 2007. - N 21(5). - Р. 295-303.
175. Role of Helicobacter pylori cagA (+) strains and specific host immune responses on the development of premalignant and malignant lesions in the gastric cardia / R.M. Jr. Peek [et al.] // Int J Cancer. - 2005. - Vol.82. - P. 520-524.
176. Role of Helicobacter pylori serology in atrophic body gastritis after eradication treatment / E. Lahner, C. Bordi, E. Di Giulio [et al] // Aliment. Pharmacol. Ther. - 2002. - Vol. 16 (3). - P. 507-513.
177. Rugge M. Secondary prevention of gastric cancer / M. Rugge // Gut. - 2007. - N 56. - Р.1646-1647.
178. Salt intake and gastric cancer risk according to Helicobacter pylori infection, smoking, tumor site and histological type / B. Peleteiro [et al.] // Br. J. Cancer. - 2011. - Vol. 104. -P.198-207.
179. Sansonetti P.J. Microbes and microbial toxins: paradigms for microbialmucosal interactions III. Shigellosis: from symptoms to molecular pathogenesis / P.J. Sansonetti // Am J Physiol. - 2001. - Vol.280. - Р. 319-323.
180. Sartor R.B. Intestinal microflora in human and experimental inflammatory bowel disease / R.B. Sartor // Curr Opin Gastroenterol. - 2001. - Vol.17. - P. 324-330.
181. Sequential alterations in gastric biopsies and tumor tissues support the multistep process of carcinogenesis / H. A1-Awadhi [et al.] // Histol Histopathol. - 2011. - N 26(9). - P. 1153-1163.
182. Sequential treatment for Helicobacter pylori eradication in duodenal ulcer patients: improving the cost of pharmacotherapy / C. Hassan [et al.] // Aliment. Pharmacol. Ther. - 2003. - Vol. 18. - P. 641-646.
183. Serologic response to lower-molecular-weight proteins of H. pylori is related to clinical outcome of H. pylori infection in Taiwan / S.C. Shiesh [et al.] // Dig Dis Sci. - 2000. - Vol.45. - P. 781-788.
184. Seropositivity to Helicobacter pylori heat shock protein 60 is strongly associated with intensity of chronic inflammation, particularly in antrum mucosa: an extension of an 18-year follow- up study of chronic gastritis in Saaremaa, Estonia / T. Vorobjova [et al.] // FEMS Immunol Med Microbiol. - 2001. - Vol.30. - P. 143-149.
185. Seroreactivity to 19.5-kDa Antigen in Combination with Absence of Seroreactivity to 35-kDa Antigen is Associated with an Increased Risk of Gastric Adenocarcinoma / T.S. Chua [et al.] // Helicobacter. - 2002. - Vol. 7, N 4. - P. 257-264.
186. Serum anti-Lewis X antibody is associated with VacA seropositivity but not atrophic gastritis in patients with Helicobacter pylori infection / T. Shimoyama [et al.] // Eur J Gastroenterol Hepatol. - 2001. - Vol.13. - P. 227- 231.
187. Sipponen P. Natural history of gastritis and its relationship to peptic ulcer disease / P. Sipponen // Digestion. - 2002. - N 51(Suppl 1). - Р.70 - 5.
188. Sipponen P. Importance of atrophic gastritis in diagnostics and prevention of gastric cancer: application of plasma biomarkers / P. Sipponen, D.Y. Graham // Scand J Gastroenterol. - 2007. - N 42. - Р. 2-10.
189. The action of bismuth against Helicobacter pylori mimics but is not caused by intracellular iron deprivation / M.V. Bland [et al.] //Antimicrob Agents Chemother. - 2004. - N 48(6). - Р.1983-7.
190. The complete genome sequence of the Helicobacter pylori / J.F. Tomb [et al.] // Nature. - 2002. - Vol.378. - P. 539-547.
191. The Helicobacter pylori vacA s1, m1 genotype and cagA is associated with gastric carcinoma in Germany / S. Miehlke [et al.] // Int J Cancer. - 2000. - Vol.87. - P. 322-327.
192. The immuno-inflammatory mechanism for tissue injury in inflammatory bowel disease and Helicobacter pyloriinfected chronic active gastritis. Roles of the mucosal immune system / H. Nagura [et al.] // Digestion. - 2001. - Vol.63. - P. 12-21.
193. The incidence of reflux oesophagitis after cure of Helicobacter pylori in a Japanese population / T. Murai [et al.] // Aliment Pharmacol Ther. - 2000. - Vol.14 (Suppl. 1) . - P. 161-165.
194. The Montreal definition and classification of gastroesophageal reflux disease: A global evidence-based consensus / N. Vakil [et al.] // Am. J. Gastroenterol. - 2006. - Vol. 101, N 8. - P. 1900-1920.
195. The N-terminal 34 kDa fragment of Helicobacter pylori vacuolating cytotoxin targets mitochondria and induces cytochrome c release / A. Galmiche [et al.] // EMBO J. - 2000. - Vol.19. - P. 6361-6370.
196. The prolongation of triple therapy for Helicobacter pylori does not allow reaching therapeutic outcome of sequential scheme: a prospective, randomized study / V. De Francesco [et al.] // Dig. Liver Dis. - 2004. - Vol. 36. - P. 322-326.
197. The seroprevalence of cagA-positive Helicobacter pylori strains in the spectrum of reflux disease / J.J. Vicari [et al.] // Gastroenterology. - 2002. - Vol.115. - P. 50-57.
198. The validity of a biomarker method for indirect detection of gastric mucosal atrophy versus standart histopathoiogy / M. Leja [et al.] // Dig. Dis. Sci. - 2009. - Vol. 54, N 11. - P. 2377-2384.
199. The Vienna classification of gastrointestinal epithelial neoplasia / R.J. Schlemper [et al.] // Gut. - 2000. - Vol. 47. - P. 251-255.
200. Translocation of Helicobacter pylori CagA into gastric epithelial cells by type IV secretion / S. Odenbreit [et al.] // Science. - 2000. - Vol.287. - P. 1497-1500.
201. Uemura N. Helicobacter pylori infection / N. Uemura // N Engl J Med. - 2000. - Vol.315. - P. 584-589.
202. Vakil N. Antimicrobial resistance and eradication strategies for Helicobacter pylori / N. Vakil // Rev Gastroenterol Disord. - 2009. - N 9. - Р. 78-88.
203. Van de Velde C.J.H. What is optimal surgery for gastric cancer? / C.J.H. Van de Velde // 13th World Congress on Gastrointestinal Cancer. - Barcelona, 2011. - P. 131-150.
204. Van Cutsem E. The diagnosis and management of gastric cancer: expert discussion and recommendations from the 12th ESMO / Worlds Congress on Gastrointestinal Cancer / E. Van Cutsem, M. Dicato, R. Geva // Ann. Oncology. - 2011. - Vol. 22 (suppl. 5). - P. 1-9.
205. Virulence factors of Helicobacter pylori responsible for gastric diseases in Mongolian gerbils / K. Ogura [et al.] // J Exp Med. - 2000. - Vol.192. - P. 1601-1610.
206. Water extract of Helicobacter pylori stimulates interleukin-8 secretion by a human gastric epithelial cell line (JR-St) through protein tyrosine phosphorylation / K. Yakabi [et al.] // J Gastroenterol Hepatol. - 2000. - Vol. 15. - P. 263-270.
207. Webb P.M. Helicobacter pylori as a risk factor for cancer / P.M. Webb // Baillieres Clin Gastroenterol. - 2003. - Vol.9. - P. 553-572.
208. Weck M.N. Prevalence of chronic atrophic gastritis in different parts of the world / M.N. Weck, H. Brenner // Cancer Epidemiol. Biomarkers Prev. - 2006. - Vol. 15, N 6. - P. 1083-1094.
209. Weel J.F. The interrelationship between cytotoxin and Helicobacter pylori-related diseases / J.F. Weel // J Infect Dis. - 2003. - Vol. 163(5). - P. 1151-1155.
210. Werdmuller B.F. Helicobacter pylori infection has no role in the pathogenesis of reflux esophagitis / B.F. Werdmuller // Dig Dis Sci. - 2002. - Vol.42. - P. 103-105.
211. Why does Japan have a high incidence of gastric cancer? Comparison of gastritis between UK and Japanese patients / G.M. Naylor, T. Gotoda, M. Dixon [et al.] // Gut. - 2006. - N 55. - Р.1545-57.
Размещено на Allbest.ru
Подобные документы
Причины возникновения острого гастрита - воспаления слизистой оболочки желудка, его патогенез, симптомы и диагностика. Хронический гастрит и функциональная диспепсия, клинические проявления и лечение, режим питания. Эрадикация Helicobacter pylori.
реферат [39,1 K], добавлен 23.01.2016Helicobacter pylori - спиралевидная грамотрицательная бактерия, которая инфицирует различные области желудка и двенадцатиперстной кишки. Научная классификация бактерии, ее форма и патогенетические механизмы действия. Пути передачи и основные заболевания.
презентация [1,7 M], добавлен 25.12.2011Острое воспаление слизистой желудка. Причины флегмонозного гастрита. Диагностика и классификация острого гастрита. Диагностика Helicobacter pylori. Лечение и режим при Helicobacter pylori. Фармакотерапия хронического химического рефлюкс-гастрита.
реферат [35,3 K], добавлен 17.03.2015Helicobacter pylori, факторы вирулентности. Гены "островка патогенности". Цитологический, уреазный, иммунологический и бактериологический метод диагностики. Выявление гена CagA H.pylori. Эндоскопические и гистологические проявления инфекции у носителей.
дипломная работа [1,4 M], добавлен 21.04.2013Хронический гастрит – заболевание, связанное с хроническим воспалением слизистой оболочки желудка, сопровождающееся нарушением секреторной, моторной, инкреторной функции этого органа. Классификация хронического гастрита. Хронический аутоиммунный гастрит.
реферат [30,7 K], добавлен 21.12.2008Диагностика бактерии Helicobacter pylori, которая инфицирует желудок. Цитологический метод исследования. Быстрый уреазный и дыхательный тест. Микробиологический, бактериологический, гистологические, иммунологические методы. Полимеразная цепная реакция.
презентация [1,6 M], добавлен 21.02.2016Воспаления слизистой оболочки желудка, их классификация и дифференциация. Гастрит как воспалительные или воспалительно-дистрофические изменения слизистой оболочки желудка. Особенности сестринского ухода при гастритах: промывание желудка, гипертермия.
контрольная работа [4,2 M], добавлен 16.02.2011Воспаление слизистой оболочки желудка. Исследование неатрофического антрального и аутоиммунного фундального атрофического гастрита. Клинические критерии болезни Менетрие. Лечение эритематозно-экссудативного, геморрагического и гиперпластического гастрита.
презентация [89,0 K], добавлен 05.06.2015Острое воспаление слизистой оболочки желудка и двенадцатиперстной кишки. Нарушения секреторной, моторной, частично инкреторной функций. Неспецифические клинические проявления. Хронический гастрит, его проявление, симптомы, виды, диагностика и лечение.
реферат [23,8 K], добавлен 27.02.2009Гастрит - собирательное понятие для обозначения воспалительных и дистрофических изменений слизистой оболочки желудка. Основные формы гастрита, особенности их патогенеза. Пищевые причины возникновения заболевания, его клинические проявления и диагностика.
презентация [334,1 K], добавлен 24.12.2013
